| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 33 | 2024 | 2332 | 3.920 |
Why?
|
| Heart Transplantation | 23 | 2023 | 800 | 1.680 |
Why?
|
| Heart-Assist Devices | 21 | 2025 | 1020 | 1.620 |
Why?
|
| Heart Failure, Systolic | 2 | 2021 | 35 | 1.230 |
Why?
|
| Diuretics | 4 | 2022 | 159 | 0.980 |
Why?
|
| Water-Electrolyte Imbalance | 3 | 2023 | 77 | 0.980 |
Why?
|
| Cardiomyopathies | 8 | 2023 | 514 | 0.870 |
Why?
|
| Child | 59 | 2025 | 26341 | 0.860 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 3 | 2022 | 28 | 0.840 |
Why?
|
| Anemia, Iron-Deficiency | 3 | 2021 | 140 | 0.840 |
Why?
|
| Hospitalization | 7 | 2024 | 1950 | 0.830 |
Why?
|
| Shock, Cardiogenic | 3 | 2024 | 176 | 0.780 |
Why?
|
| Heart Defects, Congenital | 7 | 2023 | 1889 | 0.750 |
Why?
|
| Renal Insufficiency | 3 | 2018 | 259 | 0.730 |
Why?
|
| Hyponatremia | 2 | 2023 | 73 | 0.630 |
Why?
|
| Retrospective Studies | 39 | 2024 | 17753 | 0.590 |
Why?
|
| Infant | 29 | 2025 | 13352 | 0.570 |
Why?
|
| Central Venous Pressure | 1 | 2018 | 25 | 0.560 |
Why?
|
| Child, Preschool | 32 | 2025 | 15110 | 0.560 |
Why?
|
| Creatinine | 2 | 2018 | 398 | 0.550 |
Why?
|
| Hospital Mortality | 7 | 2024 | 1064 | 0.540 |
Why?
|
| Cardiotonic Agents | 4 | 2019 | 138 | 0.510 |
Why?
|
| Extracorporeal Membrane Oxygenation | 6 | 2019 | 682 | 0.510 |
Why?
|
| Glomerular Filtration Rate | 3 | 2021 | 566 | 0.500 |
Why?
|
| Acute Kidney Injury | 6 | 2025 | 705 | 0.480 |
Why?
|
| Adolescent | 35 | 2025 | 20987 | 0.470 |
Why?
|
| Anemia | 2 | 2018 | 354 | 0.470 |
Why?
|
| Natriuretic Peptide, Brain | 4 | 2019 | 325 | 0.450 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2014 | 362 | 0.440 |
Why?
|
| Humans | 70 | 2025 | 131163 | 0.430 |
Why?
|
| Cardiovascular Agents | 2 | 2020 | 88 | 0.430 |
Why?
|
| Mortality | 1 | 2016 | 264 | 0.420 |
Why?
|
| Hospitals, Pediatric | 7 | 2018 | 808 | 0.420 |
Why?
|
| Male | 49 | 2025 | 64957 | 0.410 |
Why?
|
| Female | 47 | 2025 | 70963 | 0.380 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2014 | 268 | 0.340 |
Why?
|
| Treatment Outcome | 21 | 2025 | 12936 | 0.330 |
Why?
|
| Graft Rejection | 10 | 2023 | 552 | 0.320 |
Why?
|
| Cohort Studies | 12 | 2021 | 5063 | 0.320 |
Why?
|
| Cardiomyopathy, Hypertrophic | 3 | 2025 | 161 | 0.310 |
Why?
|
| Prognosis | 8 | 2023 | 4886 | 0.290 |
Why?
|
| Acute Disease | 5 | 2023 | 1153 | 0.290 |
Why?
|
| Risk Factors | 12 | 2024 | 11074 | 0.290 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 789 | 0.290 |
Why?
|
| Registries | 6 | 2025 | 1634 | 0.280 |
Why?
|
| Cardiology | 1 | 2014 | 514 | 0.280 |
Why?
|
| Infant, Newborn | 13 | 2021 | 8635 | 0.270 |
Why?
|
| Heart Arrest | 2 | 2014 | 356 | 0.270 |
Why?
|
| Time Factors | 9 | 2020 | 6196 | 0.270 |
Why?
|
| Young Adult | 10 | 2023 | 10103 | 0.260 |
Why?
|
| Sinoatrial Node | 1 | 2007 | 28 | 0.260 |
Why?
|
| Tertiary Care Centers | 2 | 2019 | 263 | 0.240 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2020 | 214 | 0.240 |
Why?
|
| Heart Rate | 3 | 2025 | 577 | 0.240 |
Why?
|
| Electrocardiography | 3 | 2025 | 970 | 0.240 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2020 | 216 | 0.240 |
Why?
|
| Infusions, Parenteral | 1 | 2006 | 79 | 0.240 |
Why?
|
| Milrinone | 1 | 2006 | 30 | 0.230 |
Why?
|
| Hemodynamics | 3 | 2025 | 810 | 0.230 |
Why?
|
| Incidence | 6 | 2018 | 3360 | 0.230 |
Why?
|
| Pediatrics | 2 | 2019 | 1252 | 0.230 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2025 | 21 | 0.220 |
Why?
|
| Hemodynamic Monitoring | 1 | 2025 | 17 | 0.220 |
Why?
|
| Critical Illness | 4 | 2025 | 630 | 0.220 |
Why?
|
| Pacemaker, Artificial | 1 | 2007 | 193 | 0.220 |
Why?
|
| Dopamine | 1 | 2006 | 246 | 0.210 |
Why?
|
| Adult | 12 | 2024 | 31282 | 0.210 |
Why?
|
| Risk Assessment | 5 | 2020 | 3711 | 0.210 |
Why?
|
| Sodium | 2 | 2023 | 280 | 0.210 |
Why?
|
| Coronary Stenosis | 1 | 2005 | 78 | 0.210 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2023 | 853 | 0.210 |
Why?
|
| Patient Readmission | 2 | 2020 | 442 | 0.210 |
Why?
|
| Arginine Vasopressin | 1 | 2004 | 26 | 0.210 |
Why?
|
| Length of Stay | 4 | 2019 | 1421 | 0.210 |
Why?
|
| Emergency Service, Hospital | 2 | 2009 | 1224 | 0.200 |
Why?
|
| Kidney Diseases | 1 | 2008 | 477 | 0.200 |
Why?
|
| Myocarditis | 3 | 2015 | 122 | 0.190 |
Why?
|
| Severity of Illness Index | 5 | 2016 | 3061 | 0.190 |
Why?
|
| Ambulatory Care | 1 | 2006 | 401 | 0.190 |
Why?
|
| Texas | 6 | 2016 | 3686 | 0.180 |
Why?
|
| Hypernatremia | 1 | 2023 | 32 | 0.180 |
Why?
|
| Chlorides | 1 | 2022 | 97 | 0.180 |
Why?
|
| Developmental Disabilities | 1 | 2007 | 781 | 0.180 |
Why?
|
| Flecainide | 1 | 2002 | 21 | 0.180 |
Why?
|
| Databases, Factual | 3 | 2016 | 1240 | 0.180 |
Why?
|
| Sotalol | 1 | 2002 | 33 | 0.180 |
Why?
|
| Transferrin | 1 | 2021 | 46 | 0.170 |
Why?
|
| Multivariate Analysis | 5 | 2019 | 1378 | 0.170 |
Why?
|
| Thrombosis | 2 | 2022 | 499 | 0.170 |
Why?
|
| Hypotension | 2 | 2022 | 187 | 0.170 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2002 | 104 | 0.160 |
Why?
|
| Syndrome | 3 | 2009 | 1155 | 0.160 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2020 | 45 | 0.160 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2002 | 227 | 0.160 |
Why?
|
| North America | 1 | 2020 | 255 | 0.150 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 133 | 0.150 |
Why?
|
| Comorbidity | 3 | 2020 | 1595 | 0.150 |
Why?
|
| Patient Admission | 2 | 2014 | 185 | 0.150 |
Why?
|
| Age Factors | 5 | 2020 | 2825 | 0.150 |
Why?
|
| Overweight | 1 | 2021 | 387 | 0.140 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 61 | 0.140 |
Why?
|
| Iron | 1 | 2021 | 304 | 0.140 |
Why?
|
| Postoperative Complications | 6 | 2016 | 3147 | 0.140 |
Why?
|
| Age of Onset | 1 | 2020 | 592 | 0.140 |
Why?
|
| Aorta, Thoracic | 1 | 2023 | 530 | 0.140 |
Why?
|
| Tracheostomy | 1 | 2020 | 212 | 0.130 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2016 | 1168 | 0.130 |
Why?
|
| United States | 7 | 2021 | 12072 | 0.130 |
Why?
|
| Walking | 1 | 2019 | 230 | 0.130 |
Why?
|
| Heart Ventricles | 2 | 2019 | 749 | 0.130 |
Why?
|
| Medical Records | 2 | 2016 | 174 | 0.130 |
Why?
|
| American Heart Association | 1 | 2019 | 343 | 0.130 |
Why?
|
| Echocardiography | 2 | 2018 | 1125 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2021 | 558 | 0.120 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2016 | 24 | 0.120 |
Why?
|
| Hypertrophy | 1 | 2016 | 100 | 0.110 |
Why?
|
| Hospital Charges | 1 | 2015 | 70 | 0.110 |
Why?
|
| Ventricular Dysfunction | 1 | 2015 | 24 | 0.110 |
Why?
|
| Hemoglobins | 1 | 2016 | 286 | 0.110 |
Why?
|
| Patient Discharge | 2 | 2020 | 514 | 0.110 |
Why?
|
| Disease Progression | 3 | 2016 | 2200 | 0.110 |
Why?
|
| Cardiac Catheterization | 3 | 2023 | 630 | 0.100 |
Why?
|
| Heart | 1 | 2019 | 650 | 0.100 |
Why?
|
| Drug Utilization Review | 1 | 2014 | 27 | 0.100 |
Why?
|
| Graft Survival | 4 | 2021 | 465 | 0.100 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2014 | 56 | 0.100 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2014 | 46 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2025 | 6459 | 0.100 |
Why?
|
| Isolated Noncompaction of the Ventricular Myocardium | 1 | 2014 | 45 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 1 | 2021 | 934 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2006 | 2121 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2016 | 1211 | 0.100 |
Why?
|
| Prevalence | 2 | 2018 | 2701 | 0.090 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2019 | 187 | 0.090 |
Why?
|
| Biomarkers | 2 | 2016 | 3385 | 0.090 |
Why?
|
| Stroke Volume | 2 | 2006 | 541 | 0.090 |
Why?
|
| Drug Prescriptions | 1 | 2014 | 237 | 0.090 |
Why?
|
| Liver Transplantation | 1 | 2021 | 1147 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2015 | 407 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1295 | 0.090 |
Why?
|
| Tachycardia, Ventricular | 1 | 2015 | 257 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2022 | 1826 | 0.090 |
Why?
|
| Pseudomonas Infections | 1 | 2013 | 118 | 0.090 |
Why?
|
| Candidiasis | 1 | 2013 | 134 | 0.090 |
Why?
|
| Electronic Health Records | 1 | 2019 | 844 | 0.090 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2014 | 229 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2016 | 1246 | 0.080 |
Why?
|
| Kidney | 2 | 2023 | 1282 | 0.080 |
Why?
|
| Colloids | 1 | 2009 | 15 | 0.080 |
Why?
|
| Isotonic Solutions | 1 | 2009 | 40 | 0.080 |
Why?
|
| Natriuretic Agents | 1 | 2009 | 28 | 0.080 |
Why?
|
| Predictive Value of Tests | 4 | 2008 | 2304 | 0.070 |
Why?
|
| Blood Chemical Analysis | 1 | 2009 | 79 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2021 | 1717 | 0.070 |
Why?
|
| Virus Diseases | 1 | 2011 | 285 | 0.070 |
Why?
|
| Staphylococcal Infections | 1 | 2013 | 571 | 0.070 |
Why?
|
| Ventricular Function, Left | 2 | 2022 | 549 | 0.070 |
Why?
|
| Kidney Function Tests | 1 | 2008 | 135 | 0.070 |
Why?
|
| Consanguinity | 1 | 2007 | 115 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 1071 | 0.060 |
Why?
|
| Transplantation Immunology | 1 | 2007 | 40 | 0.060 |
Why?
|
| Cachexia | 1 | 2007 | 57 | 0.060 |
Why?
|
| Electromyography | 1 | 2007 | 134 | 0.060 |
Why?
|
| Patient Selection | 2 | 2010 | 729 | 0.060 |
Why?
|
| Ticlopidine | 1 | 2006 | 28 | 0.060 |
Why?
|
| Systole | 1 | 2006 | 195 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 5196 | 0.060 |
Why?
|
| Hyperglycemia | 1 | 2008 | 234 | 0.060 |
Why?
|
| Myocardium | 2 | 2008 | 852 | 0.060 |
Why?
|
| Glycogen Storage Disease Type IIb | 1 | 2005 | 5 | 0.060 |
Why?
|
| Leukopenia | 1 | 2005 | 44 | 0.060 |
Why?
|
| Intraoperative Complications | 1 | 2007 | 154 | 0.060 |
Why?
|
| Wolff-Parkinson-White Syndrome | 2 | 2005 | 73 | 0.060 |
Why?
|
| Tachycardia | 1 | 2005 | 66 | 0.060 |
Why?
|
| Survival Rate | 2 | 2021 | 2114 | 0.060 |
Why?
|
| Reference Values | 1 | 2006 | 676 | 0.060 |
Why?
|
| Cardiac Output, Low | 1 | 2005 | 58 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2019 | 3359 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2006 | 182 | 0.050 |
Why?
|
| Codon, Nonsense | 1 | 2005 | 136 | 0.050 |
Why?
|
| Leukocytes | 1 | 2005 | 205 | 0.050 |
Why?
|
| Outpatients | 1 | 2006 | 262 | 0.050 |
Why?
|
| Cause of Death | 1 | 2007 | 506 | 0.050 |
Why?
|
| Probability | 2 | 2019 | 306 | 0.050 |
Why?
|
| Biopsy | 2 | 2023 | 1239 | 0.050 |
Why?
|
| Aortic Coarctation | 1 | 2005 | 99 | 0.050 |
Why?
|
| Pulmonary Circulation | 1 | 2004 | 113 | 0.050 |
Why?
|
| Autonomic Nervous System | 1 | 2023 | 50 | 0.050 |
Why?
|
| Obesity | 2 | 2021 | 2426 | 0.050 |
Why?
|
| Glutarates | 1 | 2023 | 39 | 0.050 |
Why?
|
| Abdominal Pain | 1 | 2005 | 319 | 0.050 |
Why?
|
| Resuscitation | 1 | 2005 | 258 | 0.050 |
Why?
|
| Dilatation | 1 | 2023 | 67 | 0.050 |
Why?
|
| Infant, Low Birth Weight | 1 | 2003 | 172 | 0.050 |
Why?
|
| Hirudins | 1 | 2022 | 39 | 0.050 |
Why?
|
| Infant Welfare | 1 | 2002 | 25 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 824 | 0.040 |
Why?
|
| Antithrombins | 1 | 2022 | 49 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 2005 | 324 | 0.040 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2002 | 61 | 0.040 |
Why?
|
| Renal Dialysis | 2 | 2021 | 951 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 663 | 0.040 |
Why?
|
| Thinness | 1 | 2021 | 71 | 0.040 |
Why?
|
| Hemolysis | 1 | 2021 | 86 | 0.040 |
Why?
|
| Coronary Vessels | 1 | 2005 | 521 | 0.040 |
Why?
|
| Mitochondrial Proteins | 1 | 2023 | 283 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 1410 | 0.040 |
Why?
|
| Heparin | 1 | 2022 | 208 | 0.040 |
Why?
|
| Benchmarking | 1 | 2020 | 137 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2019 | 53 | 0.040 |
Why?
|
| Bilirubin | 1 | 2019 | 126 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2022 | 1319 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2022 | 687 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 487 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 1173 | 0.030 |
Why?
|
| Quality of Life | 2 | 2020 | 2082 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 1618 | 0.030 |
Why?
|
| Recurrence | 1 | 2002 | 1489 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2019 | 235 | 0.030 |
Why?
|
| Risk | 1 | 2019 | 726 | 0.030 |
Why?
|
| Public Health | 1 | 2019 | 269 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2022 | 605 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2015 | 482 | 0.030 |
Why?
|
| Logistic Models | 1 | 2021 | 1797 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1129 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2019 | 471 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 501 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 1882 | 0.030 |
Why?
|
| Oxygen | 1 | 2019 | 548 | 0.030 |
Why?
|
| Coronary Care Units | 1 | 2016 | 34 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 3763 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2023 | 1590 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2016 | 195 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2009 | 1483 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 688 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2016 | 361 | 0.020 |
Why?
|
| Pseudomonas | 1 | 2013 | 15 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2015 | 247 | 0.020 |
Why?
|
| Phenotype | 1 | 2023 | 4497 | 0.020 |
Why?
|
| Heart Diseases | 2 | 2008 | 499 | 0.020 |
Why?
|
| Staphylococcus | 1 | 2013 | 68 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 555 | 0.020 |
Why?
|
| Infant Mortality | 1 | 2014 | 183 | 0.020 |
Why?
|
| Candida | 1 | 2013 | 79 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2019 | 1106 | 0.020 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2016 | 500 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 761 | 0.020 |
Why?
|
| Contraindications | 1 | 2010 | 75 | 0.020 |
Why?
|
| Forecasting | 1 | 2010 | 351 | 0.020 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2009 | 108 | 0.020 |
Why?
|
| Isoantibodies | 1 | 2008 | 59 | 0.020 |
Why?
|
| Immunoassay | 1 | 2008 | 126 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2008 | 265 | 0.020 |
Why?
|
| Assisted Circulation | 1 | 2007 | 23 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2010 | 643 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 204 | 0.020 |
Why?
|
| Stroke | 1 | 2015 | 1061 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2008 | 331 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2008 | 410 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2007 | 225 | 0.020 |
Why?
|
| Defibrillators, Implantable | 1 | 2009 | 215 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 2008 | 190 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 423 | 0.010 |
Why?
|
| Equipment Failure | 1 | 2006 | 122 | 0.010 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2005 | 8 | 0.010 |
Why?
|
| Papillary Muscles | 1 | 2005 | 18 | 0.010 |
Why?
|
| Warfarin | 1 | 2006 | 121 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2005 | 410 | 0.010 |
Why?
|
| Aspirin | 1 | 2006 | 211 | 0.010 |
Why?
|
| Muscular Diseases | 1 | 2005 | 118 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2005 | 729 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2008 | 1117 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2085 | 0.010 |
Why?
|
| Exercise | 1 | 2009 | 892 | 0.010 |
Why?
|
| Morbidity | 1 | 2003 | 256 | 0.010 |
Why?
|
| Algorithms | 1 | 2009 | 1680 | 0.010 |
Why?
|
| Mass Screening | 1 | 2008 | 822 | 0.010 |
Why?
|
| Seizures | 1 | 2007 | 890 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 981 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2007 | 910 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 2465 | 0.010 |
Why?
|
| Middle Aged | 1 | 2007 | 28601 | 0.000 |
Why?
|